Top Story

FDA grants orphan drug designation to sevuparin for sickle cell disease

March 26, 2015

The FDA granted orphan drug designation to sevuparin for the treatment of patients with sickle cell disease, according to a press release from the drug’s manufacturer.

Sevuparin (DF02, Dilaforette) is a proprietary polysaccharide drug which may restore blood flow and prevent further microvascular obstructions caused by abnormal blood cells in patients with sickle cell disease. The anti-adhesive properties of the agent could potentially treat underlying causes of vaso-occlusive crisis in patients with sickle cell disease, leading to earlier pain relief, shorter hospital stay, reduced need of opioids and improved quality of life, according to the release.

Botswana-UPenn partnership, Microsoft to launch telemedicine service in Botswana

March 26, 2015
The Botswana-UPenn Partnership, along with Microsoft, the Botswana Innovation Hub, and others are planning to launch the first telemedicine service in Africa…
Breaking News

House passes bill to repeal sustainable growth rate

March 26, 2015
By a vote of 392 to 37, the U.S. House of Representatives passed a bipartisan bill today that repeals the sustainable growth rate, a key factor in annual Medicare…
Susan G. Lakoski, MD, MS In the Journals

Cardiorespiratory fitness levels predict risk for cancer diagnosis, mortality

March 26, 2015
Middle-aged men with a high cardiorespiratory fitness level displayed decreased risks for lung and colon cancers, as well as a decreased risk for cancer-related death if…
Industry News

VB-111 plus bevacizumab confers positive interim results in recurrent glioblastoma

March 26, 2015
Interim results from an ongoing phase 2 study demonstrated that patients with recurrent glioblastoma who received VB-111 alone and subsequently with bevacizumab achieved…
More News Headlines »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
thumbnail for video 4124118507001

3D printing has applications, challenges in a variety of medical specialties

March 20, 2015
SAN FRANCISCO — Scott Hollister, PhD, professor of biomedical engineering at the University of Michigan, talks…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan